Eagle Pharmaceuticals(EGRX)
$0.65-0.25 (-27.78%)
EGRX
Eagle Pharmaceuticals financials statements
$0.65
At close:-0.25 (-27.78%)
Eagle Pharmaceuticals (EGRX) Ratios
213 Followers
Eagle Pharmaceuticals Ratios
EGRX's free cash flow for Q2 2023 was $-132.00K. For the 2023 fiscal year, EGRX's free cash flow was decreased by $-6.00K and operating cash flow was $-126.00K. See a summary of the company’s cash flow.
| Ratios | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.70 | 2.32 | 4.36 | 4.62 | 4.13 |
| Quick Ratio | 1.27 | 2.03 | 4.15 | 4.45 | 3.92 |
| Cash Ratio | 0.50 | 1.31 | 2.71 | 2.83 | 1.99 |
| Solvency Ratio | 0.28 | -0.06 | 0.25 | 0.25 | 0.46 |
| Operating Cash Flow Ratio | 0.46 | 0.38 | 1.30 | 1.44 | 1.32 |
| Short-Term Operating Cash Flow Coverage | 8.11 | 1.10 | 6.19 | 11.20 | 8.38 |
| Net Current Asset Value | $ 16.15M | $ 95.33M | $ 98.89M | $ 104.07M | $ 86.00M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.12 | 0.15 | 0.15 | 0.19 |
| Debt-to-Equity Ratio | 0.29 | 0.17 | 0.21 | 0.22 | 0.28 |
| Debt-to-Capital Ratio | 0.22 | 0.14 | 0.17 | 0.18 | 0.22 |
| Long-Term Debt-to-Capital Ratio | 0.19 | 0.00 | 0.12 | 0.16 | 0.19 |
| Financial Leverage Ratio | 1.74 | 1.44 | 1.36 | 1.42 | 1.48 |
| Debt Service Coverage Ratio | 5.02 | -0.12 | 1.83 | 2.82 | 4.26 |
| Interest Coverage Ratio | 20.01 | 1.69 | 12.79 | 8.12 | 13.38 |
| Debt to Market Cap | 0.17 | 0.04 | 0.05 | 0.05 | 0.07 |
| Interest Debt Per Share | 5.55 | 2.41 | 3.03 | 3.00 | 3.19 |
| Net Debt to EBITDA | 0.16 | -80.09 | -2.16 | -2.43 | -0.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 70.01% | 75.41% | 75.79% | 68.91% | 70.97% |
| EBIT Margin | 20.68% | -1.70% | 13.45% | 12.60% | 17.24% |
| EBITDA Margin | 24.48% | 0.49% | 15.98% | 14.98% | 18.96% |
| Operating Profit Margin | 25.57% | 1.61% | 17.55% | 11.14% | 17.17% |
| Pretax Profit Margin | 19.40% | -2.65% | 12.07% | 11.23% | 15.96% |
| Net Profit Margin | 11.26% | -5.03% | 6.38% | 7.31% | 14.96% |
| Continuous Operations Profit Margin | 11.26% | -5.03% | 6.38% | 7.31% | 14.96% |
| Net Income Per EBT | 58.02% | 189.69% | 52.87% | 65.07% | 93.73% |
| EBT Per EBIT | 75.88% | -164.25% | 68.81% | 100.84% | 92.96% |
| Return on Assets (ROA) | 8.78% | -3.40% | 4.74% | 5.62% | 13.37% |
| Return on Equity (ROE) | 15.26% | -4.89% | 6.45% | 7.99% | 19.84% |
| Return on Capital Employed (ROCE) | 27.44% | 1.54% | 15.32% | 10.11% | 18.41% |
| Return on Invested Capital (ROIC) | 15.51% | 1.34% | 7.77% | 6.43% | 16.73% |
| Return on Tangible Assets | 14.68% | -4.24% | 5.98% | 7.18% | 17.65% |
| Earnings Yield | 9.43% | -1.30% | 1.91% | 1.73% | 5.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.31 | 4.13 | 3.67 | 4.08 | 3.21 |
| Payables Turnover | 5.00 | 2.57 | 7.25 | 11.15 | 6.24 |
| Inventory Turnover | 1.99 | 1.93 | 5.63 | 9.27 | 7.46 |
| Fixed Asset Turnover | 271.07 | 104.86 | 90.42 | 88.96 | 88.99 |
| Asset Turnover | 0.78 | 0.68 | 0.74 | 0.77 | 0.89 |
| Working Capital Turnover Ratio | 3.60 | 1.52 | 1.40 | 1.48 | 1.61 |
| Cash Conversion Cycle | 195.40 | 135.69 | 113.85 | 96.06 | 104.26 |
| Days of Sales Outstanding | 84.66 | 88.29 | 99.35 | 89.44 | 113.76 |
| Days of Inventory Outstanding | 183.75 | 189.58 | 64.83 | 39.35 | 48.95 |
| Days of Payables Outstanding | 73.02 | 142.18 | 50.32 | 32.74 | 58.46 |
| Operating Cycle | 268.42 | 277.87 | 164.18 | 128.80 | 162.72 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.92 | 2.16 | 3.67 | 4.07 | 3.55 |
| Free Cash Flow Per Share | 3.91 | 2.14 | 3.62 | 4.01 | 3.54 |
| Dividend Paid and CapEx Coverage Ratio | 284.84 | 87.37 | 66.26 | 72.05 | 393.86 |
| Capital Expenditure Coverage Ratio | 284.84 | 87.37 | 66.26 | 72.05 | 393.86 |
| Operating Cash Flow Coverage Ratio | 0.75 | 0.95 | 1.30 | 1.45 | 1.18 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.16 | 0.26 | 0.29 | 0.25 |
| Free Cash Flow Yield | 13.36% | 4.20% | 7.76% | 6.68% | 8.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 10.61 | -77.03 | 52.37 | 57.74 | 18.65 |
| Price-to-Sales (P/S) Ratio | 1.19 | 3.87 | 3.34 | 4.22 | 2.79 |
| Price-to-Book (P/B) Ratio | 1.62 | 3.77 | 3.38 | 4.61 | 3.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 7.48 | 23.82 | 12.88 | 14.97 | 11.39 |
| Price-to-Operating Cash Flow Ratio | 7.46 | 23.55 | 12.68 | 14.76 | 11.36 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 0.44 | -3.63 | -1.11 | -0.50 |
| Enterprise Value Multiple | 5.04 | 704.51 | 18.75 | 25.74 | 13.86 |
| Enterprise Value | 390.53M | 596.72M | 562.90M | 755.15M | 560.64M |
| EV to EBITDA | 5.04 | 704.51 | 18.75 | 25.74 | 13.86 |
| EV to Sales | 1.23 | 3.48 | 3.00 | 3.85 | 2.63 |
| EV to Free Cash Flow | 7.73 | 21.39 | 11.55 | 13.68 | 10.73 |
| EV to Operating Cash Flow | 7.70 | 21.15 | 11.37 | 13.49 | 10.70 |
| Tangible Book Value Per Share | 5.43 | 9.66 | 9.89 | 9.00 | 6.97 |
| Shareholders’ Equity Per Share | 18.06 | 13.52 | 13.80 | 13.03 | 10.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.42 | -0.90 | 0.47 | 0.35 | 0.06 |
| Revenue Per Share | 24.48 | 13.14 | 13.93 | 14.24 | 14.44 |
| Net Income Per Share | 2.76 | -0.66 | 0.89 | 1.04 | 2.16 |
| Tax Burden | 0.58 | 1.90 | 0.53 | 0.65 | 0.94 |
| Interest Burden | 0.94 | 1.56 | 0.90 | 0.89 | 0.93 |
| Research & Development to Revenue | 0.11 | 0.30 | 0.16 | 0.19 | 0.21 |
| SG&A to Revenue | 0.31 | 0.39 | 0.40 | 0.38 | 0.27 |
| Stock-Based Compensation to Revenue | 0.05 | 0.11 | 0.13 | 0.11 | 0.09 |
| Income Quality | 1.42 | -3.27 | 4.13 | 3.91 | 1.64 |
Currency in USD

